PharmaMar KOL Event

June 10, 2020

General Agenda

Access event HERE:

Guest speaker Dr Hossein Borghaei (Fox Chase Cancer Center, Philadelphia and American Lung Association, Lung Cancer Expert Medical Advisory Panel) will discuss SCLC and Lurbinectedin.

RSVP to Patrick Till (


  • Small Cell Lung Cancer Disease Overview
  • Current Standard of Care – 1st and 2nd line treatments
  • Lurbinectedin Monotherapy data
  •  How Lurbinectedin will potentially be used in clinic
RSVP for Event / Log Back in Presenter Access

Additional menu options can be found in the menu bar on the left or at the top.

PharmaMar SA [PHM:ES]
Rev­enue gen­er­at­ing with marine-de­rived and nov­el MoA on­col­o­gy prod­ucts. Yon­delis (soft tis­sue sar­co­ma and ovarian can­cer) com­mer­cial­ized with di­rect sales-force in EU and part­n­er­ship in US with Janssen. Signed li­cens­ing agree­ment with Jazz Phar­ma for lur­binecte­din in the US - up­front pay­ment of $200M, $100mm on ap­pro­val and up to $550M sales mile­s­tones. [more in­for­ma­tion]